Actinium Pharmaceuticals to Present at Biotech Showcase™ 2018 and Participate in Partnering Sessions

On January 3, 2018 Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or "the Company") reported that the Company will be attending the Biotech Showcase 2018 being held January 8-10, 2018 at the Hilton San Francisco: Union Square in San Francisco, California (Press release, Actinium Pharmaceuticals, JAN 3, 2018, View Source [SID1234522841]). Representatives from Actinium’s business development, clinical development and executive teams will be attending the conference, and will be available for one-on-one meetings during the conference. To arrange an investor meeting with Actinium please contact, Steve O’Loughlin, Actinium’s Principal Financial Officer at [email protected] and to arrange a business development meeting please contact David Gould, M.D., Actinium’s Senior Vice President, Corporate Development & Corporate Affairs at [email protected]. Meetings can also be scheduled through the partneringONE system View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Information for Actinium’s presentation are as follows:

Date: Monday, January 8, 2018
Time: 10:00 AM PT
Track: Yosemite – A (Ballroom Level)
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco

About Biotech Showcase

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.